FDA hands Bristol Myers a landmark approval in early-stage lung cancer after just five days
On Feb. 28, the FDA accepted Bristol Myers Squibb’s application for approval of a new use of blockbuster checkpoint inhibitor Opdivo and said it would …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
